FR16C0028I2 - VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS - Google Patents

VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS

Info

Publication number
FR16C0028I2
FR16C0028I2 FR16C0028C FR16C0028C FR16C0028I2 FR 16C0028 I2 FR16C0028 I2 FR 16C0028I2 FR 16C0028 C FR16C0028 C FR 16C0028C FR 16C0028 C FR16C0028 C FR 16C0028C FR 16C0028 I2 FR16C0028 I2 FR 16C0028I2
Authority
FR
France
Prior art keywords
viral vectors
therapeutic methods
vectors
methods
treat disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR16C0028C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Georgetown University
Catherex Inc
Original Assignee
General Hospital Corp
Georgetown University
Catherex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23067509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR16C0028(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by General Hospital Corp, Georgetown University, Catherex Inc filed Critical General Hospital Corp
Publication of FR16C0028I1 publication Critical patent/FR16C0028I1/en
Application granted granted Critical
Publication of FR16C0028I2 publication Critical patent/FR16C0028I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation
    • C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16671—Demonstrated in vivo effect

Abstract

The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.
FR16C0028C 2001-03-27 2016-06-15 VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS Active FR16C0028I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27906901P 2001-03-27 2001-03-27
PCT/US2002/009512 WO2002076216A1 (en) 2001-03-27 2002-03-27 Viral vectors and their use in therapeutic methods

Publications (2)

Publication Number Publication Date
FR16C0028I1 FR16C0028I1 (en) 2016-07-22
FR16C0028I2 true FR16C0028I2 (en) 2018-05-11

Family

ID=23067509

Family Applications (1)

Application Number Title Priority Date Filing Date
FR16C0028C Active FR16C0028I2 (en) 2001-03-27 2016-06-15 VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS

Country Status (9)

Country Link
US (6) US7749745B2 (en)
EP (1) EP1381280B1 (en)
JP (2) JP4212897B2 (en)
AT (1) ATE508635T1 (en)
AU (1) AU2002306919B2 (en)
CA (1) CA2441663C (en)
ES (1) ES2366608T3 (en)
FR (1) FR16C0028I2 (en)
WO (1) WO2002076216A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
AU2002306919B2 (en) 2001-03-27 2007-11-22 Tomoki Todo Viral vectors and their use in therapeutic methods
EP1487983A4 (en) * 2002-03-01 2007-08-15 Sloan Kettering Inst Cancer Prevention of recurrence and metastasis of cancer
CA2561691A1 (en) * 2004-03-31 2005-11-03 Tomoki Todo Method of constructing recombinant herpes simplex virus
AU2005228788B2 (en) * 2004-03-31 2010-12-02 Tomoki Todo Anticancer activity enhancer of viral therapy and method of cancer prevention or treatment
US7731952B2 (en) * 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US8703120B2 (en) * 2008-05-29 2014-04-22 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
US9267151B2 (en) * 2008-08-20 2016-02-23 Brainco Biopharma, S.L. STXBP1 overexpressing mouse and its uses in screening of treatments for neuropsychiatric illness
JPWO2011101912A1 (en) 2010-02-19 2013-06-17 国立大学法人 東京大学 Recombinant herpes virus and pharmaceutical composition comprising recombinant herpes virus
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
DK2753355T3 (en) * 2011-09-08 2019-01-28 Univ New York ONCOLYTIC HERP SIMPLEX VIRUSES AND THERAPEUTIC APPLICATIONS THEREOF
US10201575B2 (en) * 2013-10-28 2019-02-12 University of Pittsburgh—of the Commonwealth System of Higher Education Oncolytic HSV vector
MA39818A (en) 2014-03-30 2017-02-08 Benevir Biopharm Inc Exogenous tap inhibitor "armed" oncolytic viruses and therapeutic uses thereof
IL300202B2 (en) 2014-12-18 2024-04-01 Amgen Inc Stable frozen herpes simplex virus formulation
WO2016205429A1 (en) 2015-06-15 2016-12-22 New York University Method of treatment using oncolytic viruses
JP6959258B2 (en) 2016-01-08 2021-11-02 レプリミュン リミテッド Modified oncolytic virus
KR20180136435A (en) 2016-01-27 2018-12-24 온코루스, 인크. Tumor-like viral vectors and uses thereof
US11091775B2 (en) 2016-06-22 2021-08-17 Oregon Health And Science University Recombinant cytomegalovirus vectors as vaccines for tuberculosis
WO2018006005A1 (en) 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
AU2018235944B2 (en) 2017-03-15 2024-01-04 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
CN106974942A (en) * 2017-05-03 2017-07-25 武汉滨会生物科技股份有限公司 Application of the recombination oncolytic II herpes simplex virus types in anti-lymphadenoma, cancer of the esophagus, breast cancer, pancreatic cancer drug is prepared
AU2018306455A1 (en) 2017-07-26 2020-02-27 Virogin Biotech Canada Ltd Oncolytic viral vectors and uses thereof
SI3661954T1 (en) 2017-08-03 2022-05-31 Amgen Inc. Interleukin-21 muteins and methods of treatment
JP2020530003A (en) 2017-08-07 2020-10-15 アムジェン インコーポレイテッド Treatment of three-type negative breast cancer or colorectal cancer with liver metastasis with anti-PD-L1 antibody and oncolytic virus
SG11202001499WA (en) 2017-09-08 2020-03-30 Amgen Inc Inhibitors of kras g12c and methods of using the same
EP3697806A4 (en) 2017-10-17 2021-10-27 International AIDS Vaccine Initiative, Inc. Tuberculosis antigen cassettes
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
BR112020014121A2 (en) 2018-01-12 2020-12-01 Amgen Inc. anti-pd-1 antibodies and treatment methods
JP7429046B2 (en) 2018-03-30 2024-02-07 具紀 藤堂 Swelling-inhibiting oncolytic virus
EP3653716A1 (en) * 2018-11-19 2020-05-20 HSF Pharmaceuticals Replication-competent controlled alpha-herpesvirus virus vectors and uses therefore
CA3124690A1 (en) 2018-12-27 2020-07-02 Amgen Inc. Lyophilized virus formulations
MX2021010458A (en) 2019-03-05 2021-09-21 Amgen Inc Use of oncolytic viruses for the treatment of cancer.
TW202102543A (en) 2019-03-29 2021-01-16 美商安進公司 Use of oncolytic viruses in the neoadjuvant therapy of cancer
US20230147832A1 (en) * 2020-01-22 2023-05-11 City Of Hope Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer
WO2024038857A1 (en) * 2022-08-16 2024-02-22 具紀 藤堂 Pharmaceutical composition containing herpes simplex virus vector

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2659628B1 (en) * 1990-03-16 1992-09-18 Marin S Communication BOX OR CASE DEVICE WITH MOBILE COVER.
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
GB9102126D0 (en) 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
US5750398A (en) * 1993-11-30 1998-05-12 David C. Johnson Vector, element and method for inhibiting immune recognition
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
US6261552B1 (en) * 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
US5824318A (en) * 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
ATE282708T1 (en) * 2000-01-21 2004-12-15 Biovex Ltd HERPES VIRUS STRAINS FOR GENE THERAPY
EP1286678A2 (en) * 2000-06-01 2003-03-05 Sloan-Kettering Institute For Cancer Research Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer
AU2002306919B2 (en) * 2001-03-27 2007-11-22 Tomoki Todo Viral vectors and their use in therapeutic methods

Also Published As

Publication number Publication date
ES2366608T3 (en) 2011-10-21
ATE508635T1 (en) 2011-05-15
US20020187163A1 (en) 2002-12-12
EP1381280A1 (en) 2004-01-21
US8470577B2 (en) 2013-06-25
JP2004528836A (en) 2004-09-24
CA2441663C (en) 2013-01-22
JP2009060907A (en) 2009-03-26
US20200345835A1 (en) 2020-11-05
US20170290908A1 (en) 2017-10-12
CA2441663A1 (en) 2002-10-03
US7749745B2 (en) 2010-07-06
AU2002306919B2 (en) 2007-11-22
US9555072B2 (en) 2017-01-31
US20130280299A1 (en) 2013-10-24
US10532095B2 (en) 2020-01-14
US20110070262A1 (en) 2011-03-24
US8871193B2 (en) 2014-10-28
EP1381280B1 (en) 2011-05-11
EP1381280A4 (en) 2006-06-14
US20150071965A1 (en) 2015-03-12
JP4212897B2 (en) 2009-01-21
WO2002076216A1 (en) 2002-10-03
FR16C0028I1 (en) 2016-07-22

Similar Documents

Publication Publication Date Title
FR16C0028I2 (en) VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS
DK1556021T3 (en) Pharmaceutical compositions comprising flavonoids and menthol as well as methods of treatment using said compositions
NO20050795L (en) Compounds, compositions and methods for utilizing the same
NO20053817D0 (en) Preparations and Methods for Antiviral Combination Therapy.
DK1368060T3 (en) HMGB1 protein inhibitors and / or antagonists for the treatment of vascular disease
NO20041917L (en) Specific agents that bind human angiopoietin-2
BR0309665A (en) Treatment of alpha-galactosidase deficiency at
BRPI0411900A (en) antiviral compounds and methods
DE60327999D1 (en) AZOLYLAMINOAZINES AS INHIBITORS OF PROTEIN KINASES
ATE376832T1 (en) DELAYED RELEASE FORMULATIONS OF OXYMORPHONE
BRPI0412845A (en) herpes virus, use of a virus, pharmaceutical composition, and method of treating a tumor in an individual in need thereof
DE60137337D1 (en) PREVENTIVE AND THERAPEUTIC MONOCLONAL ANTIBODIES AGAINST VACCINIAVIRUSANTIGENE
WO2003032916A3 (en) Organosulfur inhibitors of tyrosine phosphatases
HUP0303917A2 (en) Combinations of sterol absorption inhibitir(s) with blood modifier(s) and their use for treating vascular conditions
CY1107531T1 (en) USE OF PROTECTION ANALYTES FOR THE TREATMENT OF DRY EYE DISORDERS
DK1097173T3 (en) Use of IL-2 peptides and derivatives thereof as therapeutic agents
MXPA04006572A (en) Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections.
CL2004000261A1 (en) PROCEDURE FOR THE ELIMINATION OF VIRUSES IN THERAPEUTIC APPLICATION FIBRINOGEN SOLUTIONS.
EA200400399A1 (en) METHODS OF TREATMENT OF PULMONARY DISEASES
DE602005016552D1 (en) PARAPOCK VIRUS IN COMBINATION WITH OTHER ANTIVIRAL AGENTS FOR THE TREATMENT OF HIV / AIDS
NO20051301L (en) Proteintyrosinforfataseinhibitorer
DE602004019541D1 (en) CYCLOALKYLÄBÜ CONDENSED INDOLE
DK1461042T3 (en) Use of desoxypeganine in the treatment of clinical depression
EA200000909A1 (en) FORM VI 5,6-DICHLOR-2- (ISOPROPYLAMINO) -1- (b-L-RIBOFURANOSIL) -1H-BENZIMIDAZOLE
NO20005548L (en) Mykobakterieinhibitorer